TEVA241220C16500
- 5.74
- 0.000.00%
Teva Pharmaceutical Industries Newsroom
FDA Approves First Generic of Novo Nordisk's Victoza
Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
Trending Stocks in Bearish Pre-holiday Week for U.S. Stock Market
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
Express News | Form 144 | Teva Pharmaceutical Industries(TEVA.US) Insider Proposes to Sell 6.09 Million in Common Stocks
Teva Pharmaceutical Industries Ltd. to Release Q4 and Full Year 2024 Financial Results on January 29, 2025
Teva Pharmaceutical Industries Options Spot-On: On December 20th, 113.39K Contracts Were Traded, With 981.61K Open Interest
US MOVERS & SHAKERS Dec 16-Dec 20, 2024
UBS Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $28
Teva Pharmaceutical Industries Options Spot-On: On December 18th, 95,900 Contracts Were Traded, With 952.86K Open Interest
Jim Cramer on Teva Pharmaceutical Industries (TEVA): A Game-Changer for Intractable Disease Treatments?
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Teva Pharmaceutical Stock Positioned for Even Better Performance in 2025, UBS Says
Express News | U.S. Supreme Court Agrees To Hear South Carolina's Bid To End Public Funding Of Abortion Provider Planned Parenthood
Teva Pharmaceutical Indus Analyst Ratings
FDA Approves Celltrion's Biosimilar of J&J's Stelara
Express News | Teva : BofA Global Research Raises Price Objective to $25 From $23
Daily short sale tracking: NVIDIA's short volume increased by 5 million, with a short sale ratio of 10%